XML 40 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Organization and Basis of Presentation (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 08, 2025
Jul. 02, 2025
Jun. 02, 2023
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Dec. 31, 2024
Aug. 19, 2024
Jun. 30, 2024
Dec. 31, 2023
Apr. 09, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total stockholders equity       $ 4,912,254 $ 1,366,936 $ 4,912,254 $ 1,366,936 $ 651,456 $ 827,219   $ 2,246,139 $ 3,994,762  
Proceeds from issuance of private placement   $ 5,050,000.00       4,178,162            
Gross proceeds $ 1,500,000         2,245,040            
Net loss       1,980,398 986,030 3,465,626 2,968,271            
Net cash used in operations           1,982,720 2,565,861            
Cash       2,887,874   2,887,874     1,038,952       $ 40,000
Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contractual obligation       510,000   510,000              
Minimum [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total stockholders equity                   $ 2,500,000      
Common Stock [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Reverse stock split     1-for-10                    
Total stockholders equity       570 225 570 225 $ 276 $ 225   $ 225 $ 225  
Net loss                  
Common Stock [Member] | Minimum [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Bid price     $ 1.00